Related to Banyan to Develop Biomarkers for Emory University’s Phase III Traumatic Brain Injury Study

• Banyan Gets $26.3M to Develop Point-of-Care Diagnostic for Brain Injury
  
• Transgenomic Picks Up Clinical Data’s MDx and Biomarker Business for $15.4M
  
• ChipDX Finds 163-Gene Signature that Predicts Early-Stage Colon Cancer Progression
  
• AltheaDx and Compendia Launch Breast Cancer Segregation Panel
  
• Investigators Identify Prognostic Marker for Treating Hep C with Peg-Interferon and Ribavirin
  
• MDxHealth to Develop Companion Diagnostic for Pfizer Cancer Candidate
  
• Life Technologies, Oxford BRC, AstraZeneca, and ORD Ally on Cancer Diagnostic Project
  
• Roche Taps Evotec to Identify Biomarkers of Cancer Drug Activity and Patient Response
  
• Pfizer Gains Patent from Cell Signaling Technology to Enhance Companion Diagnostic Efforts
  
• SuppreMol Taps Protagen’s Biomarker Expertise for Phase IIa Systemic Lupus Erythematosus Study
  
• Clarient, Acorn Ally to Standardize Cancer Testing
  
• TrovaGene Gains Rights to Mutations Associated with Chronic Lymphocytic Leukemia
  
• Foundation and Sanofi Sign Deal for Cancer Biomarkers and Companion Diagnostics
  
• Qiagen Signs Two Biomarker Deals and Confirms Japanese Okay for EGFR Companion Dx
  
• Erytech, ExonHit Share €8.9M Initial OSEO Funding for Enzyme Depletion Anticancer Project
  
• Developing a New Biomarker-Based Cancer CDx
  
• Firms Flock to Epic’s CTC Platform
  
• Partnership Seeks Multiple Myeloma Biomarkers and Drugs
  
• Response Genetics Offers New Test for Lung Cancer Biomarker
  
• Myriad, Sanofi Forge Potentially $10M Diabetes Collab